- Home
- DXR
as 07-26-2024 4:00pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 43.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 861.0 |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.96 | EPS Growth: | -17.30 |
| 52 Week Low/High: | $7.11 - $10.13 | Next Earning Date: | 01-01-0001 |
| Revenue: | $34,671,972 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Daxor Corporation (DXR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Michel Robert J | DXR | Chief Financial Officer | Mar 27 '24 | Buy | $8.70 | 750 | $6,525.00 | 11,300 | SEC Form 4 |
| Feuer Edward | DXR | Director | Mar 4 '24 | Buy | $7.21 | 1,000 | $7,210.00 | 1,000 | SEC Form 4 |
| Michel Robert J | DXR | Chief Financial Officer | Dec 6 '23 | Buy | $7.75 | 120 | $930.00 | 10,550 | SEC Form 4 |
| Michel Robert J | DXR | Chief Financial Officer | Dec 1 '23 | Buy | $7.75 | 180 | $1,395.00 | 10,430 | SEC Form 4 |
| Michel Robert J | DXR | Chief Financial Officer | Nov 24 '23 | Buy | $7.94 | 500 | $3,970.00 | 10,250 | SEC Form 4 |
Latest Daxor Corporation News
DXR Breaking Stock News: Dive into DXR Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer
GlobeNewswire
16 days ago
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
GlobeNewswire
a month ago
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
GlobeNewswire
2 months ago
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
GlobeNewswire
3 months ago
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
GlobeNewswire
3 months ago
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
GlobeNewswire
4 months ago
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
GlobeNewswire
4 months ago
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
Compare DXR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.